Anti-Human CD38 (HB-7) - DyLight® 488
| Code | Size | Price |
|---|
| LEI-C1002-25ug | 25 ug | £186.00 |
Quantity:
| LEI-C1002-100ug | 100 ug | £335.00 |
Quantity:
| LEI-C1002-500ug | 500 ug | £588.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: Mouse IgG1 κ
Antibody Clonality: Monoclonal
Antibody Clone: HB-7
Regulatory Status: RUO
Target Species: Human
Application: Functional Study
Shipping:
2 - 8°C Wet Ice
Storage:
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
CD38 is expressed on plasma cells, other lymphoid and myeloid cell populations, natural killer cells, B cells, activated T cells, some peripheral regulatory T cells, monocytes, lymph node germinal center lymphoblasts, intrafollicular cells, dendritic cells, erythrocytes, platelets, committed stem cells, Purkinje cells, neurofibrillary tangles in the brain, epithelial cells in the prostate, β?cells in the pancreas, retinal cells in the eye, and sarcolemma of smooth and striated muscle. CD38 can also be detected on early osteoclast progenitors but not on osteoblasts and mature osteoclasts. CD38 expression is very high and uniform on all malignant cells in multiple myeloma. While generally found on the plasma membrane, CD38 has also been detected in the cytosol or nucleus in brain, pancreatic acinar cells, smooth muscle, and osteoclasts.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 488
Format:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
BJAB Human B-cell Line
Long Description:
CD38 is a type II transmembrane glycoprotein that functions as an adhesion molecule with ectoenzymatic activities that contribute to intracellular calcium mobilization 1,2. Dysregulation is associated with a number of diseases, including HIV, autoimmune, type II diabetes mellitus, osteoporosis, and hematological malignancies such as multiple myeloma (MM) 1, a neoplasm characterized by clonal expansion of malignant plasma cells 2.
Because CD38 is strongly and uniformly expressed on myeloma cells, but has limited expression on normal cells, anti-CD38 antibody HB-7 was used to develop an antibody drug conjugate (ADC) capable of killing human myeloma and lymphoma cell lines 3. This ADC is composed of HB-7 conjugated to a chemically modified ricin molecule and is able to block protein synthesis in multiple myeloma cells and in normal bone marrow mononuclear cells.
HB-7 was developed by immunizing BALB/c mice with viable cells of the Human Burkitt lymphoma B cell line BJAB 4. The antibody binds to an epitope in the carboxyl terminus of CD38 between residues 273-285, which is also the site of enzyme activity 5. Binding is unaffected by the presence of NAD+ and does not influence CD38 catalytic activity 6.
NCBI Gene:
952
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
CD38
References
1. van de Donk NW, Janmaat ML, Mutis T, et al. Immunol Rev. 270(1):95-112. 2016.
2. Morandi F, Horenstein AL, Costa F, et al. Front Immunol. 9:2722. 2018.
3. Goldmacher VS, Bourret LA, Levine BA, et al. Blood. 84(9):3017-3025. 1994.
4. Tedder TF, Clement LT, Cooper MD. Tissue Antigens24(3):140-149. 1984.
5. Hoshino S, Kukimoto I, Kontani K, et al. J Immunol.;158(2):741-747. 1997.
6. Berthelier V, Laboureau J, Boulla G, et al. Eur J Biochem. 267(10):3056-3064. 2000.
7. Collins A, Rothman N, Liu K, et al. JCI Insight. 2(5):e90063. 2017.
8. Caeser R, Di Re M, Krupka JA, et al. Nat Commun. 10(1):4543. 2019.
9. Imura Y, Ando M, Kondo T, et al. JCI Insight. 5(14):e136185. 2020.
10. Caeser R, Gao J, Di Re M, et al. Nat Protoc. 16(5):2499-2519. 2021.
11. Shukla S, Ying W, Gray F, et al. Nat Chem Biol. 17(7):784-793. 2021.
12. Nachmias B, Khan DH, Voisin V, et al. Leukemia. 36(5):1283-1295. 2022.
13. Volodarsky I, Shimoni S, Haberman D, J Cardiovasc Dev Dis. 10(1):2. 2022.
Related Products
| Product Name | Product Code | Supplier | Anti-Human CD38 (HB-7) - FITC | LEI-C1001 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human CD38 (HB-7) - DyLight® 550 | LEI-C1003 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD38 (HB-7) - DyLight® 650 | LEI-C1004 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD38 (HB-7) - DyLight® 594 | LEI-C1005 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD38 (HB-7) - APC | LEI-C998 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD38 (HB-7) - PE | LEI-C999 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||